摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Adamantan-2-yl-piperidine | 259228-64-3

中文名称
——
中文别名
——
英文名称
2-Adamantan-2-yl-piperidine
英文别名
2-(2-Adamantyl)piperidine
2-Adamantan-2-yl-piperidine化学式
CAS
259228-64-3
化学式
C15H25N
mdl
——
分子量
219.37
InChiKey
XNMHSNFFGAZILT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    12
  • 氢给体数:
    1
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-Adamantan-2-yl-piperidinepotassium carbonate 作用下, 以 二氯甲烷 为溶剂, 反应 27.5h, 生成
    参考文献:
    名称:
    Synthesis, conformational characteristics and anti-influenza virus A activity of some 2-adamantylsubstituted azacycles
    摘要:
    The broad-spectrum antiviral activity of 2-(2-adamantyl)piperidines 11, 13a,b, and 15, 3-(2-adamantyl)pyrrolidines 27, 21a-g and 2-(2-adamantylmethyl)piperidines 30, 32a-c, and 35a-d was examined. Several compounds in the new series were potent against influenza A H3N2 virus. When 1-aminoethyl pharmacophore group of 2-rimantadine 4 (2-isomer of rimantadine) is included into a saturated nitrogen heterocycle, see compound 11, potency was retained. The diamine derivatives 21e-g and particularly 35a-c possessing three pharmocophoric groups, that is, the adamantyl and the two amine groups, exhibited high potency. The new compounds did not afford specific activity at non-toxic concentrations against any of the other viruses tested. According to NMR spectroscopy and molecular mechanics calculations it is striking that the parent structures 11 and 27 adopt a fixed trans conformation around C2-C2' bond. In the parent amines, which proved to be active compounds, the distance between nitrogen and adamantyl pharmacophoric groups was different; N-C2' distance is 3.7, 3.8 angstrom for 27, 30 and 2.5 angstrom for 11 suggesting that M2 receptor site can accommodate different in size and orientation lipophilic cages. (c) 2006 Elsevier Inc. All rights reserved.
    DOI:
    10.1016/j.bioorg.2006.05.004
  • 作为产物:
    描述:
    2-吡啶基锂platinum(IV) oxide 氢氧化钾 、 sodium tetrahydroborate 、 氯化亚砜氢气 作用下, 以 四氢呋喃甲醇乙醚乙醇二氯甲烷 为溶剂, 反应 38.0h, 生成 2-Adamantan-2-yl-piperidine
    参考文献:
    名称:
    2-(2-金刚烷基)哌啶的合成和结构抗流感病毒使用NMR光谱学和分子建模相结合的活性关系研究。
    摘要:
    合成2-(2-金刚烷基)哌啶13和15a-c,并评估其抗流感病毒A和B的活性。母体NH化合物13对H2N2流感A的活性比金刚烷胺和金刚烷胺高3-4倍。13的N-烷基化导致衍生物15a-c缺乏生物活性。从计算化学和NMR光谱学的结合推论,这种生物活性的显着降低可能归因于NH和N-烷基哌啶之间的构象性质不同。
    DOI:
    10.1016/s0960-894x(99)00631-9
点击查看最新优质反应信息

文献信息

  • [EN] ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS<br/>[FR] COMPLEXES ORGANOMÉTALLIQUES DE TRANSITION POUR LE TRAITEMENT DES INFECTIONS VIRALES
    申请人:BUSATH DAVID D
    公开号:WO2015192037A1
    公开(公告)日:2015-12-17
    Organo-transition metal complexes possess anti-viral inhibitory activity against influenza A, including the S3 IN mutant. The organo-transition metal complexes include a transition metal and at least one ligand based on the structure of an M2 proton channel blocker. Compounds and pharmaceutical compositions are useful for treating viruses such as influenza A.
    有机过渡金属配合物具有抗流感病毒的抑制活性,包括S3 IN突变体。有机过渡金属配合物包括过渡金属和至少一种基于M2质子通道阻滞剂结构的配体。这些化合物和药物组合物对治疗流感病毒等病毒有用。
  • Compositions and kits for treating influenza
    申请人:Adamas Pharmaceuticals, Inc.
    公开号:EP2450040A2
    公开(公告)日:2012-05-09
    Compositions, kits and methods are provided for the treatment or prophylaxis of influenza
    提供了用于治疗或预防流感的组合物、试剂盒和方法
  • Synthetic catalase/superoxide dismutase mimetics and methods for treating viral infections
    申请人:THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES
    公开号:US10683316B2
    公开(公告)日:2020-06-16
    The invention provides for the treatment of disorders related to viral infection, using salen manganese compounds.
    本发明利用沙林锰化合物治疗与病毒感染有关的疾病。
  • COMPOSITIONS AND KITS FOR TREATING INFLUENZA
    申请人:Adamas Pharmaceuticals, Inc.
    公开号:EP2142192B1
    公开(公告)日:2012-02-15
  • METHODS FOR SCREENING SUBSTANCES CAPABLE OF MODULATING THE REPLICATION OF AN INFLUENZA VIRUS
    申请人:Institut National de la Santé et de la Recherche Médicale (INSERM)
    公开号:EP2710381A2
    公开(公告)日:2014-03-26
查看更多